The safety and efficacy of amivantamab-vmjw was evaluated in the CHRYSALIS trial, a phase I, open-label, multicenter, dose escalation and dose expansion study that included patients with advanced NSCLC with EGFR exon20ins mutation. This evidence concerns the gene EGFR and non-small cell lung carcinoma.